Therefore, it is necessary to continue the search for new alternatives to α–glucosidase and pancreatic lipase inhibitors, with milder side effects and which contribute to the treatment of obesity and type 2 diabetes mellitus, in conjunction with current therapies. This evidence concerns the gene PNLIP and diabetes mellitus.